|2.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||Graft vs Host Disease (Graft-Versus-Host Disease)
|1.||Razonable, Raymund R: 12 articles (01/2015 - 03/2002)|
|2.||Cairns, Nigel J: 11 articles (10/2015 - 06/2004)|
|3.||Navarro, David: 11 articles (08/2015 - 09/2008)|
|4.||Potena, Luciano: 11 articles (07/2013 - 03/2003)|
|5.||Lautenschlager, Irmeli: 11 articles (10/2008 - 08/2002)|
|6.||Solano, Carlos: 10 articles (08/2015 - 02/2002)|
|7.||Gerna, Giuseppe: 9 articles (03/2015 - 12/2003)|
|8.||Lilleri, Daniele: 9 articles (03/2015 - 12/2003)|
|9.||Inoue, Naoki: 8 articles (03/2015 - 02/2008)|
|10.||Boeckh, Michael: 8 articles (01/2015 - 01/2002)|
|1.||Ganciclovir (Cytovene)FDA LinkGeneric
08/01/1999 - "Ganciclovir is a nucleoside analogue with an excellent safety record; it is effective against cytomegalovirus infection in both its intravenous and its oral form. "
01/01/1999 - "The antiviral nucleoside analogue ganciclovir is a potent inhibitor of replication in herpes viruses and is effective against cytomegalovirus infections in immunocompromised patients. "
04/01/1995 - "The first patient showed marked improvement in pulmonary symptoms resulting from cytomegalovirus infection by means of gancyclovir treatment. "
11/01/1991 - "The safety and efficacy of a 10-day course of ganciclovir therapy was assessed in 17 consecutive patients with proven cytomegalovirus infection. "
11/01/1993 - "Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients. "
08/01/1989 - "The three patients with cytomegalovirus infection who were treated with foscarnet had a prolonged remission of symptoms. "
04/01/1988 - "Based on limited data, foscarnet, a pyrophosphate analogue, also appears to have some efficacy in treating cytomegalovirus infection. "
06/29/1985 - " In clinical trials to treat cytomegalovirus infection in immunocompromised patients, constant serum levels of between 100-450 mcgmol of phosphonoformate have been achieved in 140 subjects. "
04/01/1999 - "Foscarnet is an antiviral agent commonly used for managing patients with cytomegalovirus infection. "
05/01/1998 - "Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection."
|3.||Antiviral Agents (Antivirals)IBA
09/01/1993 - "Three of the four EBV-positive patients showed clinical improvement with antiviral agents prescribed for concomitant cytomegalovirus infection. "
01/01/2009 - "Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events."
04/15/2005 - "Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection."
11/01/1989 - "Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents in vivo."
01/01/1985 - "All of these approaches, as well as the continued development of more effective antiviral agents, will be needed for control of cytomegalovirus infection."
|4.||Acyclovir (Aciclovir)FDA LinkGeneric
05/25/1989 - "Acyclovir decreased the incidence of documented cytomegalovirus infection (with or without symptomatic disease) to 36 percent from 61 percent among the patients who received the placebo (P = 0.011). "
12/01/1987 - "Epstein-Barr virus and human cytomegalovirus infections do not seem to respond to acyclovir therapy, although in-vitro effects on these viruses may be seen. "
01/01/1987 - "Treatment of experimental cytomegalovirus infections with acyclovir."
07/28/1984 - "Acyclovir for cytomegalovirus infection."
09/01/1983 - "The use of acyclovir for cytomegalovirus infections in the immunocompromised host."
08/01/2011 - "Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection."
02/01/2013 - "Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection."
01/01/2012 - "[Successful treatment of congenital cytomegalovirus infection with valganciclovir]."
08/01/2011 - "We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. "
04/15/2011 - "Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. "
|6.||Cyclosporine (Ciclosporin)FDA LinkGeneric
08/01/2014 - "Ciclosporin levels, Epstein-Barr virus and cytomegalovirus infections did not influence the incidence of operations. "
06/01/2011 - "The risk factors of rehospitalization were: use of mycophenolate mofetile (P = .0072), use of cyclosporine (P = .0073), and cytomegalovirus infection (P < .001). "
04/01/1999 - "Two patients needed to be treated with intravenous cyclosporine A after antiviral therapy because of persistence of clinical symptoms despite the elimination of cytomegalovirus infection. "
01/01/1998 - "In seven patients GBS was attributed to cytomegalovirus infection and in the eighth patient to cyclosporin A neurotoxicity. "
06/05/1992 - "In contrast, no CRPu was demonstrated when the course was normal and in individual cases of cyclosporin renal toxicity, as well as in 27 of 34 cases of cytomegalovirus infection. "
07/15/2009 - "Adverse events were consistent with class effects including less-frequent cytomegalovirus infection with everolimus (4 [4.4%]) than MMF (14 [16.9%], P=0.01). "
05/15/2005 - "Use of everolimus was also associated with lower rates of cytomegalovirus infection in both indications. "
11/27/2004 - "The incidence of cytomegalovirus infection was significantly lower in patients receiving either 1.5 or 3 mg/day everolimus than in those receiving MMF (5.2% and 7.6% vs. 19.4%, respectively) (P = .001). "
04/01/2013 - "Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation."
07/01/2013 - "Randomized trials of everolimus in de novo heart transplantation have also consistently shown reduced cytomegalovirus infection versus antimetabolite therapy. "
|8.||DNA (Deoxyribonucleic Acid)IBA
01/01/2012 - "A neonate with reduced cytomegalovirus DNA copy number and marked improvement of hearing in the treatment of congenital cytomegalovirus infection."
08/01/1992 - "In those with uncomplicated cytomegalovirus, infection occurred earlier (p less than 0.05) but was eliminated more quickly (p less than 0.0005), and the number of infected hepatocytes was greater (p less than 0.05) when compared with those with the vanishing bile duct syndrome; in these, cytomegalovirus DNA was detectable until death or retransplantation. "
05/01/2006 - "In Japan, the umbilical cord is kept clean and dry as a symbol of the mother-to-child bond, and in recent studies, cytomegalovirus deoxyribonucleic acid was successfully detected from dried umbilical cord of two 1-year-old children who were clinically suspected of having had congenital cytomegalovirus infection. "
11/01/1992 - "[Effects of cytomegalovirus infection in pregnant women to fetuses: study with DNA-DNA hybridization method]."
11/01/2013 - "All the patients were suspected to have cytomegalovirus infection and had undergone real-time PCR of the aqueous humor to determine the amount of cytomegalovirus DNA. "
01/01/2011 - "There have been a number of studies on immunoglobulin injection into fetuses or mothers during pregnancy for the treatment of congenital cytomegalovirus infection. "
05/01/1999 - "Although large-scale studies are needed to establish the real efficacy and the best therapeutic regimen, cytomegalovirus immunoglobulin may be considered for treatment or prevention of fetal cytomegalovirus infection."
10/23/1987 - "In five controlled studies, cytomegalovirus infection developed in a total of 52 of 172 (30 percent) immunoglobulin recipients and 71 of 165 (43 percent) control patients not given globulin. "
05/01/1999 - "Cytomegalovirus immunoglobulin was administered to a pregnant woman with primary cytomegalovirus infection and placental involvement of 1 twin fetus, in whom growth restriction had developed. "
01/01/1990 - "Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection."
|10.||cidofovir (Vistide)FDA Link
01/01/2011 - "Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection."
11/01/2002 - "Cidofovir is a nucleotide analog marketed for the treatment of human cytomegalovirus infections in immunocompromised patients. "
07/01/2000 - "Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection."
11/01/2001 - "Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections."
01/15/2001 - "Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. "
|1.||Transplantation (Transplant Recipients)
08/01/2007 - "Modern antiviral strategies are effective in controlling the clinical syndromes associated with acute cytomegalovirus infection in heart transplant recipients. "
02/01/1989 - "[Prophylactic and therapeutic treatment of cytomegalovirus infections in kidney transplant recipients]."
10/01/1996 - "Improved survival with cytomegalovirus infection after intestinal transplantation in children."
11/01/1983 - "Outstanding problems remaining to be resolved are the improvement in the antileukaemic conditioning prior to transplantation and the prevention or treatment of cytomegalovirus infection in the seropositive recipient. "
01/01/2014 - "Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study."
11/01/2009 - "Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection."
12/01/2008 - "Quantitative monitoring of human cytomegalovirus infections is helpful in determining appropriate antiviral management in patients who receive bone marrow transplants. "
06/01/2005 - "Improvement in isolation of human peripheral blood leukocyte subpopulations: application in diagnosing human cytomegalovirus infection in bone marrow transplant patients."
01/01/1996 - "It still entails the drawback of severe toxicity, but progress has been made in the last 15 years, particularly with regard to improved prevention and treatment of host-versus-graft disease and severe cytomegalovirus infection. "
04/01/2012 - "Post-renal transplant cytomegalovirus infection: study of risk factors."
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
03/01/1991 - "Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening."
10/01/1987 - "Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group."
01/01/2009 - "Human cytomegalovirus infection is still a major complication after pediatric bone marrow transplantation and could be fatal in some cases. "
05/01/2004 - "Cytomegalovirus infection after bone marrow transplantation in children."
02/01/2002 - "[Detection of cytomegalovirus infection with the polymerase chain reaction and antigenemia after allogenic bone marrow transplantation]."
12/01/2011 - "Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials."
01/01/2007 - "The objective of our study was to evaluate reactivation rate of cytomegalovirus infection after kidney transplantation in Kaunas University of Medicine Hospital and its relation to anticytomegalovirus prophylaxis. "
04/15/1982 - "[Cytomegalovirus infections following kidney transplantation - clinical and serological studies of the early and late phases]."
11/01/2015 - "Cytomegalovirus infection in kidney transplantation is associated with increased morbidity and mortality through direct and indirect effects. "
11/01/2015 - "[Immunomonitoring for cytomegalovirus infection in kidney transplantation: Development and prospects]."
|5.||Hematopoietic Stem Cell Transplantation
10/01/2014 - "[Clinical study of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation]."
05/01/2014 - "[Clinical study on cytomegalovirus infection after hematopoietic stem cell transplantation in 26 patients with primary immunodeficiency diseases]."
03/01/2010 - "The aim of this study was to analyse the incidence and risk factors for cytomegalovirus infection (CMV-I) and disease (CMV-D) after a reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (alloHSCT-RIC). "
10/01/2015 - "[Clinical Analysis of Cytomegalovirus Infection after Different Patterns of Hematopoietic Stem Cell Transplantation]."
02/01/2015 - "[Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation]."